Clinical Trial Detail

NCT ID NCT04262154
Title Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Atezolizumab + Leuprolide + Prednisone

Age Groups: senior adult

No variant requirements are available.